Hyperhomocysteinemia in patients with mild chronic renal failure

N R Robles1, J Romero, L Gomez Casero

  • 1Sección de Nefrología, Hospital Infanta Cristina, Carretera de Portugal s/n E-06070, Badajoz, Spain. nroblesp@meditex.es

Insights

High homocysteine (a substance in the blood) is very common in patients with mild renal failure. This suggests early evaluation for vitamin supplementation is needed for kidney health.

Area of Science:

  • Nephrology
  • Clinical Biochemistry

Background:

  • Mild renal failure is associated with various metabolic disturbances.
  • Elevated homocysteine levels are a potential complication of impaired kidney function.

Purpose of the Study:

  • To determine the prevalence of high plasma homocysteine levels in patients experiencing mild renal failure.
  • To assess the impact of methionine loading on homocysteine levels in this cohort.

Main Methods:

  • Study included 46 patients with chronic renal failure (mean creatinine clearance 50.6 ml/min) and 35 controls.
  • Plasma homocysteine was measured at baseline and after an oral methionine challenge.
  • Patients with severe renal failure were excluded from the analysis.

Main Results:

  • Patients with mild renal failure exhibited significantly higher baseline homocysteine levels compared to controls (16.5 vs. 10.4 micromol/l, p<0.0001).
  • After methionine loading, 83% of patients with mild renal failure presented with hyperhomocysteinemia.
  • A substantial number of patients (34) and controls (4) had elevated homocysteine at baseline.

Conclusions:

  • Hyperhomocysteinemia is a highly prevalent condition in individuals with mild renal failure.
  • Early assessment of vitamin supplementation needs is recommended for patients in the initial stages of chronic kidney disease.
Abstract

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...